行情

MRTX

MRTX

Mirati
NASDAQ

实时行情|Nasdaq Last Sale

92.17
-2.43
-2.57%
盘后: 92.17 0 0.00% 16:43 02/14 EST
开盘
94.42
昨收
94.60
最高
95.03
最低
91.39
成交量
19.67万
成交额
--
52周最高
132.59
52周最低
55.11
市值
39.55亿
市盈率(TTM)
-19.6684
分时
5日
1月
3月
1年
5年

分析师评级

15位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

MRTX 新闻

  • Mirati Therapeutics Announces Initial Data In Renal Cell Carcinoma From Ongoing Investigator Sponsored Clinical Trial Of Sitravatinib In Combination With Nivolumab At The 2020 ASCO Genitourinary Cancers Syposium
  • PR Newswire.2天前
  • Biotechs Feel The Bern
  • Seeking Alpha - Article.02/03 14:30
  • Benzinga's Top Upgrades, Downgrades For January 28, 2020
  • Benzinga.01/28 14:43
  • BMO likes Seattle Genetics in premarket analyst action
  • Seeking Alpha - Article.01/28 12:15

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
-0.16%

热门股票

名称
价格
涨跌幅

MRTX 简况

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company develops product candidates to address the genetic and immunological promoters of cancer. Its clinical programs consist of two product candidates: MRTX849, a Kirsten Rat Sarcoma (KRAS) G12C inhibitor, and Sitravatinib, a multi-kinase inhibitor. Its KRAS inhibitor program is focused on the discovery and development of small molecule compounds that target KRAS G12C and G12D. MRTX849 is designed to inhibit KRAS G12C mutations which are present in non-small cell lung cancer (NSCLC) adenocarcinoma patients, colorectal cancer (CRC) patients, pancreatic cancer patients, as well as several other difficult-to-treat cancers. Sitravatinib is a spectrum-selective kinase inhibitor designed to inhibit receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET.
展开

Webull提供Mirati Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。